Holocene Advisors Trims Stake in Cooper Companies

Hedge fund reduces holdings in medical device firm by 16.1% in Q3

Mar. 16, 2026 at 11:06am

Got story updates? Submit your updates here. ›

Holocene Advisors LP, a major institutional investor, reduced its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 16.1% during the third quarter of 2026, according to a recent 13F filing with the Securities and Exchange Commission. The hedge fund now owns approximately 1.72 million shares of the medical device company, valued at around $117.8 million.

Why it matters

Cooper Companies is a leading global provider of vision care and women's health products, so changes in major institutional ownership can signal shifts in market sentiment around the company's performance and outlook. Holocene's decision to trim its position may reflect broader concerns about the stock's valuation or the company's growth prospects.

The details

According to the 13F filing, Holocene Advisors sold 328,977 shares of Cooper Companies during the third quarter, reducing its total position to 1,717,723 shares. The hedge fund now owns approximately 0.86% of the company's outstanding stock. Cooper Companies' share price has fluctuated in recent months, with the stock trading between $61.78 and $89.83 over the past year.

  • Holocene Advisors reduced its Cooper Companies holdings during the third quarter of 2026.

The players

Holocene Advisors LP

A hedge fund that manages a portfolio of investments, including a position in The Cooper Companies, Inc.

The Cooper Companies, Inc.

A global medical device company that develops, manufactures, and markets a broad range of vision care and women's health products.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Holocene Advisors' stake in Cooper Companies could signal broader concerns about the medical device firm's performance or valuation, though the reasons behind the hedge fund's decision are not explicitly stated. Investors will likely continue to monitor Cooper Companies' financial results and market position as the company navigates the evolving healthcare landscape.